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INDOLE COMPOUNDS AND THEIR USE AS
RADIATION SENSITIZING AGENTS AND
CHEMOTHERAPEUTIC AGENTS

radiation sensitiZer, yielding thermal enhancement factors of
up to 5.0 (Kampinga and Dikomey, 2001; Raaphorst and
AZZam, 1983). HoWever, hyperthermia is limited clinically as
a result of the technical problems of heat delivery (Nielsen et
al., 2001). Hence there is an urgent need to develop pharma
cological agents that can be used to replace hyperthermia.

PRIOR APPLICATIONS

This invention claims bene?t to US. Patent Application

Previous Work has established that indomethacin can act as a

No. 61/194,754, ?led Sep. 30, 2008, the contents ofWhich is

radiation sensitiZer (Bradbury et al., 2001 ; Locke et al., 2002)
and enhancer of thermal radiosensitiZation, and also it has
been shoWn from other independent Work that indomethacin
loWers the temperature necessary for the heat-induced protein
aggregation and loWers the temperature necessary for Hsf-l

incorporated herein in its entirety.
FIELD OF THE INVENTION

Generally, the present invention relates to the ?eld of radia
tion sensitiZers. Additionally, the present invention relates to

the ?eld of chemotherapeutic agents.

activation, such that a complete heat shock response can be
attained at temperatures that are by themselves, insuf?cient
for activation. Although indomethacin is used as a radiation

One aspect of the present invention relates to novel indole
compounds. Another aspect of the present invention relates to

trations. Hence there is a need to invent pharmacological

the use of indole compounds as radiation sensitiZers.
Another aspect of the present invention relates to the use of

agents With loWer toxicity.
The present inventors previously discovered novel indole

indole compounds as chemotherapeutic agents.
Another aspect of the present invention is 5-((N-benZyl

sensitiZer in radiotherapy, it is highly toxic at high concen

20

1H-indol-3-yl)methylene)pyrimidine-2,4,6(1H,3H,5H)-tri

tionally, the present inventors previously discovered (Z)-2
(N -benZyl indol -3 -ylmethylidene) quinuclidin-3 -ol
and

ones & (Z)-5-((N-benZyl-1H-indol-3-yl)methylene)imida

Z-(z)-2-[N-(4-chlorobenZyl)indole-3-ylmethylidene]quinu

Zolidine-2,4-diones and analogs thereof. Another aspect of
the present invention is the use of 5-((N-benZyl-1H-indol-3

25

yl)methylene)pyrimidine-2,4,6(1H,3H,5H)-triones & (Z)-5
ones and analogs thereof as radiation sensitiZers.

Another aspect of the present invention is 4-((3-((2,4,6
30

dol-1-yl)methyl)benZo-nitrile, and Methyl-4-((3-((2,4,6-tri
oxotetrahydro pyrimidin-5(6H)-ylidene)methyl)- 1 H-indol

dif?cult to achieve such temperatures in tumors. In order to
loWer the temperatures, the above compounds Were modi?ed
and tested for their ability to induce heat shock effect and

?nally radiosensitiZation.
The indole derived Aplysinopsin analogs have been
reported as potent and selective cytotoxic agents against can

1-yl)methyl)benZoate, and uses thereof, including the uses
described herein.
These and other aspects and uses Would be evident to one

clidin-3-ol as potent thermal radiosensitiZers capable of loW

ering the threshold for Hsfl activation and thermal sensitivity
(Sekhar et al. 2007; Sonar et al. 2007). These compounds
needed 410 C. temperature to produce radiosensitiZation. It is

((N-benZyl-1H-indol-3 -yl)methylene)imidaZolidine-2,4-di
Tri oxotetrahydropyrimidin- 5 (6H)-ylidene)methyl) - 1 H-in

as potent thermal radiosensitiZers capable of loWering the
threshold for Hsfl activation and thermal sensitivity. Addi

35

of ordinary skill in the art.

cer cells. These observations prompted us to design and syn
thesiZe a series of novel indole derivatives, including substi

tuted 5 ((N-BenZyl- 1 H-indol-3 -yl)methylene)pyrimidine-2,
BACKGROUND OF THE INVENTION

Radiotherapy is the treatment of cancer and other diseases

4,6(1H,3H,5H)-triones & (Z)-5((N-benZyl-1H-indol-3-yl)
40

methylene)imidaZolidine-2,4-diones and their related
compounds With various substitutions onboth the indolic ring

With ioniZing radiation. Radiotherapy is used in curative

and the N-benZyl group that are radiation sensitiZers by elimi

therapy, palliative therapy, adjuvant therapy after or before

nating the necessity of heat.

surgery, simultaneous radio-chemotherapy, etc. Radio

therapy is successful because ioniZing radiation kills dividing
cells and is thus slightly more toxic to fast groWing cancer
cells. Radiotherapy may be used to treat localiZed solid

45

SUMMARY AND ASPECTS OF THE PRESENT
INVENTION

50

The present invention comprises novel structural entities
have been designed and synthesiZed that constitute a series of
novel functionaliZed indole analogs and other molecules
structurally related to indomethacin in order to maximiZe

tumors, such as cancers of the skin, tongue, larynx, brain,
breast, or uterine cervix. Agents Which are used to potentiate

the effectiveness of radiation therapy in destroying unWanted
cells are radiation sensitiZing agents. Various attempts have
been made to develop a radiation sensitiZer that reduces the

radiosensitiZation activity and minimize toxicity.

radiation dose and adverse drug reactions Without compro

Another object of the present invention is to provide a
radiotherapy enhancer that can reduce the radiation dose and
adverse drug reactions When used in combination With cancer

mising the therapeutic effect of radiotherapy.
For example, 7-Hydroxystaurosporine (UCN-Ol) is used
as a radiosensitiZing agent (Zhouguang et al., 2003) in radio
therapy to increase the radiosensitivity of tumor cells. The

55

One embodiment of the present invention is a series of

sulfonamide-substituted indolinones have been invented as

radiation sensitiZing agents (Anthony et al., US. Pat. Appl.
Publ. 2004, 46 pp), Which are capable of enhancing radio

therapy by inhibiting DNA-protein kinase (DNA-PK).

radiotherapy.

60

Radiotherapy is often performed for various types of can

novel substituted N-benZyl aplysinopsin analogs Were syn
thesiZed by aldol condensation of the appropriate substituted
N-benZyl indole-3-carboxaldehyde With a selection of active
methylene compounds like barbituric acid & its related com
pounds, hydantoin & its related compounds. The structure

cers such as gastric cancer, colorectal cancer, pancreatic can

and purity of these derivatives Was veri?ed by 1H and 13 C

cer, head and neck cancer, esophageal cancer, lung cancer,

NMR spectroscopy.
As a result, novel substituted 5((N-BenZyl-1H-indol-3 -yl)

and breast cancer that are advanced to stage III or IV.

Radiation therapy combined With adjuvant hyperthermia
has the potential to provide outstanding local-regional control
for refractory disease. Hyperthermia is an extremely effective

65

methylene)pyrimidine-2,4,6(1H,3H,5H)-triones & (Z)-5

((N-benZyl-1H-indol-3 -yl)methylene)imidaZo -lidine-2,4-di
ones and their related compounds Were synthesized and

US 8,304,421 B2
3

4

evaluated for their radiosensitiZation properties against

DETAILED DESCRIPTION OF THE INVENTION

HT-29 cells. Also, embodiments Were tested against tubule
formation by HUVECs to assess their potency to inhibit

The present invention can be understood more readily by
reference to the folloWing detailed description of the inven
tion and the Examples included therein.

angiogenesis. As an example, Compound 1 inhibited the
tubule formation by HUVECs, shoWn beloW.
An additional aspect of the present invention is a cancer

Before the present compounds, compositions, and/or

treatment method provided by using a composition of the

methods are disclosed and described, it is to be understood

present invention and radiation in combination. Tumors for
Which this treatment method can be used are not particularly

that they are not limited to speci?c synthetic methods unless
otherWise speci?ed, or to particular reagents unless otherWise

limited. This method is particularly suitable for cancers With

speci?ed, as such may, of course, vary. It is also to be under

high radiation sensitivity. HoWever, since the radiation

stood that the terminology used herein is for the purpose of
describing particular aspects only and is not intended to be
limiting. Although any methods and materials similar or

enhancer of the present invention can also increase radiation
sensitivity of cancers that are considered to have loW sensi
tivity, improvement of the effect of cancer radiotherapy can
be expected. Examples of such cancers include head and neck
cancer, esophageal cancer, gastric cancer, colorectal cancer,

liver cancer, gallbladder/bile duct cancer, pancreatic cancer,
lung cancer, breast cancer, bladder cancer, prostate cancer,
cervical cancer, brain tumor, malignant lymphoma, acute leu

equivalent to those described herein can be used in the prac

tice or testing of the present invention, example methods and
materials are noW described.

20

The publications discussed herein are provided solely for
their disclosure prior to the ?ling date of the present applica

kemia, chronic leukemia, medulloblastoma, retina retino

blastoma, neuroblastoma, Wilms’ tumor, Hodgkin’s disease,
multiple myeloma, plasmacytoma, thymoma, basal cell can

tion. Nothing herein is to be construed as an admission that

the present invention is not entitled to antedate such publica

cer, squamous cancer, EWing’s tumor, thyroid cancer, ovary

cancer, salivary gland cancer, teratoma, malignant mela
noma, neuroglioma, renal cell carcinoma, osteosarcoma, and

All publications mentioned herein are incorporated herein
by reference to disclose and describe the methods and/or
materials in connection With Which the publications are cited.

25

tion by virtue of prior invention. Further, the dates of publi
cation provided herein can be different from the actual pub
lication dates, Which need to be independently con?rmed.

so forth.

The ?gures are presented as being exemplary of the present

As used in the speci?cation and the appended claims, the
singular forms “a,” “an” and “the” include plural referents
unless the context clearly dictates otherWise. Thus, for
example, reference to “a functional group,” “an alkyl,” or “a

invention, and are not to be construed as being limiting

residue” includes mixtures of tWo or more such functional

BRIEF DESCRIPTION OF THE DRAWINGS
30

thereof. In general, the ?gures shoW experimental data that
provide evidence of the radiation sensitiZation properties of
the indole analogs described herein.

groups, alkyls, or residues, and the like.
35

FIG. 1 is a chart that shoWs the results of test in connection

When such a range is expressed, a further aspect includes
from the one particular value and/or to the other particular

With Compound 1. More speci?cally, Compound 1 Was tested
on HT-29 cells for colony formation assay. Various concen
trations of Compound 1 Was used to assess the potency of the

40

compound in exerting radiation sensitiZation property. HT-29
cells Were treated With Compound 1 for 30 min and various
doses of radiation Was applied. The cells Were incubated for
90 min more. The cells Were Washed With PBS and fresh
medium Was added. Colonies that Were formed after 2 Weeks

45

of incubation, Were counted and corrected for drug toxicity
and expressed as survival fraction.
FIG. 2: HT-29 cells Were treated With Compound 1 for 2
hrs. The drug Was Washed off With PBS and fresh medium Was
added. The cells Were incubated for 5 more hours and nuclear

50

protein Was extracted and Gel Mobility Shift Assay Was per
formed as described in Experimental section, beloW.
FIG. 3: Nuclear extracts obtained above Were used to detect

synthesiZed (compounds 1, 2, 7, 8, 9, and 10) in the present

Where said event or circumstance occurs and instances Where
it does not.

As used herein, the term “subject” refers to a target of
administration. The subject of the herein disclosed methods
can be a vertebrate, such as a mammal, a ?sh, a bird, a reptile,
60

Was assessed by looking under microscope. Compound 1
inhibited tubule formation.
FIG. 6 shoWs YTR increases radiation-induced phospho
rylation of H2AX, a biochemical measure of DNA double
strand breaks
FIG. 7 shoWs inhibition of tumor groWth in connection
With the present invention.

there are a number of values disclosed herein, and that each
value is also herein disclosed as “about” that particular value
in addition to the value itself. For example, if the value “10”
is disclosed, then “about 10” is also disclosed. It is also
understood that each unit betWeen tWo particular units are
also disclosed. For example, if 10 and 15 are disclosed, then
ll, l2, l3, and 14 are also disclosed.
As used herein, the terms “optional” or “optionally” means

can not occur, and that the description includes instances
55

investigation Were analyZed for radiation sensitiZation.
FIG. 5: HUVECs Were plated on Matrigel, then treated
Wither DMSO or Compound 1 for 24 hrs. Tubule formation

value. Similarly, When values are expressed as approxima
tions, by use of the antecedent “about,” it Will be understood
that the particular value forms a further aspect. It Will be
further understood that the endpoints of each of the ranges are
signi?cant both in relation to the other endpoint, and inde
pendently of the other endpoint. It is also understood that

that the subsequently described event or circumstance can or

the expression of HSP70 protein by Western Blot. Actin Was
used as loading control.
FIG. 4 shoWs the e?iciency of various drugs that Were

Ranges can be expressed herein as from “about” one par

ticular value, and/or to “about” another particular value.

or an amphibian. Thus, the subject of the herein disclosed
methods can be a human, non-human primate, horse, pig,

rabbit, dog, sheep, goat, coW, cat, guinea pig or rodent. The
65

term does not denote a particular age or sex. Thus, adult and
neWbom subjects, as Well as fetuses, Whether male or female,
are intended to be covered. A patient refers to a subject
afflicted with a disease or disorder. The term “patient”

includes human and veterinary subjects.

US 8,304,421 B2
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As used herein, the term “treatment” refers to the medical
management of a patient With the intent to cure, ameliorate,
stabilize, or prevent a disease, pathological condition, or dis
order. This term includes active treatment, that is, treatment

daily dose can be divided into multiple doses for purposes of

administration. Consequently, single dose compositions can
contain such amounts or submultiples thereof to make up the

daily dose. The dosage can be adjusted by the individual

directed speci?cally toWard the improvement of a disease,
pathological condition, or disorder, and also includes causal
treatment, that is, treatment directed toWard removal of the
cause of the associated disease, pathological condition, or
disorder. In addition, this term includes palliative treatment,
that is, treatment designed for the relief of symptoms rather
than the curing of the disease, pathological condition, or
disorder; preventative treatment, that is, treatment directed to

physician in the event of any contraindications. Dosage can

minimizing or partially or completely inhibiting the develop

Additionally, When used in reference to compounds of the
invention, “an effective amount” refers to doses of compound

vary, and can be administered in one or more dose adminis

trations daily, for one or several days. Guidance can be found

in the literature for appropriate dosages for given classes of
pharmaceutical products. In further various aspects, a prepa
ration can be administered in a “prophylactically effective
amount”; that is, an amount effective for prevention of a
disease or condition.

ment of the associated disease, pathological condition, or

suf?cient to provide circulating concentrations high enough

disorder; and supportive treatment, that is, treatment
employed to supplement another speci?c therapy directed
toWard the improvement of the associated disease, pathologi
cal condition, or disorder.
As used herein, the term “prevent” or “preventing” refers to

to impart a bene?cial effect on the recipient thereof for at least
either treating tumors or cancers, or enhancing radiation
therapy. The precise amount to be administered can be deter
20

precluding, averting, obviating, forestalling, stopping, or hin
dering something from happening, especially by advance

mined by the skilled practitioner in vieW of desired dosages,
side effects and medical history of the patient.
As used herein, the term “pharmaceutically acceptable car

action. It is understood that Where reduce, inhibit or prevent

rier” refers to sterile aqueous or nonaqueous solutions, dis

are used herein, unless speci?cally indicated otherWise, the

persions, suspensions or emulsions, as Well as sterile poWders
for reconstitution into sterile injectable solutions or disper
sions just prior to use. Examples of suitable aqueous and
nonaqueous carriers, diluents, solvents or vehicles include

use of the other tWo Words is also expressly disclosed.
As used herein, the term “radiation sensitizer” can be con

25

strued as an agent that enhances the anti-tumor effect more

than irradiation alone by using the sensitizer in combination
With irradiation.
As used herein, the terms “administering” and “adminis
tration” refer to any method of providing a pharmaceutical
preparation to a subject. Such methods are Well knoWn to
those skilled in the art and include, but are not limited to, oral

administration, transderrnal administration, administration

by inhalation, nasal administration, topical administration,
intravaginal administration, ophthalmic administration,

Water, ethanol, polyols (such as glycerol, propylene glycol,
polyethylene glycol and the like), carboxymethylcellulose
30

35

intraaural administration, intracerebral administration, rectal

administration, and parenteral administration, including
injectable such as intravenous administration, intra-ar‘terial

and suitable mixtures thereof, vegetable oils (such as olive

oil) and inj ectable organic esters such as ethyl oleate. Proper
?uidity can be maintained, for example, by the use of coating
materials such as lecithin, by the maintenance of the required
particle size in the case of dispersions and by the use of
surfactants. These compositions can also contain adjuvants
such as preservatives, Wetting agents, emulsifying agents and
dispersing agents. Prevention of the action of microorgan
isms can be ensured by the inclusion of various antibacterial

40

administration, intramuscular administration, and subcutane

and antifungal agents such as paraben, chlorobutanol, phenol,

ous administration. Administration can be continuous or

sorbic acid and the like. It can also be desirable to include
isotonic agents such as sugars, sodium chloride and the like.

intermittent. In various aspects, a preparation can be admin
istered therapeutically; that is, administered to treat an exist
ing disease or condition. In further various aspects, a prepa

can be brought about by the inclusion of agents, such as
aluminum mono stearate and gelatin, Which delay absorption.

Prolonged absorption of the injectable pharmaceutical form
45

lnj ectable depot forms are made by forming microencapsule
matrices of the drug in biodegradable polymers such as poly

ration can be administered prophylactically; that is,
administered for prevention of a disease or condition.
As used herein, the term “effective amount” refers to an
amount that is su?icient to achieve the desired result or to

lactide-polyglycolide, poly(orthoesters) and poly(anhy

have an effect on an undesired condition. For example, a 50

release can be controlled. Depot injectable formulations are

“therapeutically effective amount” refers to an amount that is
suf?cient to achieve the desired therapeutic result or to have
an effect on undesired symptoms, but is generally insuf?cient

also prepared by entrapping the drug in liposomes or micro
emulsions Which are compatible With body tissues. The

to cause adverse side affects. The speci?c therapeutically

effective dose level for any particular patient Will depend
upon a variety of factors including the disorder being treated
and the severity of the disorder; the speci?c composition
employed; the age, body Weight, general health, sex and diet
of the patient; the time of administration; the route of admin
istration; the rate of excretion of the speci?c compound
employed; the duration of the treatment; drugs used in com
bination or coincidental With the speci?c compound
employed and like factors Well knoWn in the medical arts. For

55

injectable formulations can be sterilized, for example, by
?ltration through a bacterial-retaining ?lter or by incorporat
ing sterilizing agents in the form of sterile solid compositions
Which can be dissolved or dispersed in sterile Water or other

sterile inj ectable media just prior to use. Suitable inert carriers
can include sugars such as lactose. Desirably, at least 95% by
60

Weight of the particles of the active ingredient have an effec
tive particle size in the range of 0.01 to 10 micrometers.

Additionally, Examples of pharmaceutically acceptable
salts include alkaline or alkaline earth metal ion salts, par
ticularly Na+ or K+ salts, or similar pharmaceutically-accept

example, it is Well Within the skill of the art to start doses of a

compound at levels loWer than those required to achieve the
desired therapeutic effect and to gradually increase the dos
age until the desired effect is achieved. If desired, the effective

drides). Depending upon the ratio of drug to polymer and the
nature of the particular polymer employed, the rate of drug

65

able inorganic salts. The above salt forms in all polymorphic
and amorphous forms, may be in some cases hydrates or
solvates With alcohols and other solvents.
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As used herein, the term “substituted” is contemplated to

Examples of cycloalkyl groups include, but are not limited to,

include all permissible substituents of organic compounds. In

cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, norbornyl,

a broad aspect, the permissible substituents include acyclic

organic compounds. For purposes of this disclosure, the het

and the like. The term “heterocycloalkyl” is a type of
cycloalkyl group as de?ned above, and is included Within the
meaning of the term “cycloalkyl,” Where at least one of the
carbon atoms of the ring is replaced With a heteroatom such
as, but not limited to, nitrogen, oxygen, sulfur, or phosphorus.
The cycloalkyl group and heterocycloalkyl group can be sub
stituted or unsubstituted. The cycloalkyl group and heterocy

eroatoms, such as nitrogen, can have hydrogen substituents

cloalkyl group can be substituted With one or more groups

and cyclic, branched and unbranched, carbocyclic and het
erocyclic, and aromatic and nonaromatic substituents of

organic compounds. Illustrative substituents include, for
example, those described beloW. The permissible substituents
can be one or more and the same or different for appropriate

and/or any permissible substituents of organic compounds

including, but not limited to, optionally substituted alkyl,

described herein Which satisfy the valences of the heteroat

cycloalkyl, alkoxy, amino, ether, halide, hydroxy, nitro, silyl,

oms. This disclosure is not intended to be limited in any

sulfo-oxo, or thiol as described herein.

manner by the permissible substituents of organic com

The term “alkenyl” as used herein is a hydrocarbon group

pounds. Also, the terms “substitution” or “substituted Wit ”

of from 2 to 24 carbon atoms With a structural formula con

include the implicit proviso that such substitution is in accor
dance With permitted valence of the substituted atom and the

taining at least one carbon-carbon double bond. Asymmetric

substituent, and that the substitution results in a stable com

include both the E and Z isomers. This can be presumed in
structural formulae herein Wherein an asymmetric alkene is
present, or it can be explicitly indicated by the bond symbol

pound, e.g., a compound that does not spontaneously undergo
transformation such as by rearrangement, cycliZation, elimi
nation, etc.

structures such as (AlA2)C:C(A3A4) are intended to
20

C:C. The alkenyl group can be substituted With one or more

The term “alkyl” as used herein is a branched or

groups including, but not limited to, optionally substituted

unbranched saturated hydrocarbon group of l to 24 carbon

alkyl, cycloalkyl, alkoxy, alkenyl, cycloalkenyl, alkynyl,
cycloalkynyl, aryl, heteroaryl, aldehyde, amino, carboxylic

atoms, such as methyl, ethyl, n-propyl, isopropyl, n-butyl,
isobutyl, s-butyl, t-butyl, n-pentyl, isopentyl, s-pentyl, neo
pentyl, hexyl, heptyl, octyl, nonyl, decyl, dode cyl, tetradecyl,

25

acid, ester, ether, halide, hydroxy, ketone, aZide, nitro, silyl,
sulfo-oxo, or thiol, as described herein.
The term “cycloalkenyl” as used herein is a non-aromatic

hexadecyl, eicosyl, tetracosyl, and the like. The alkyl group
can be cyclic or acyclic. The alkyl group can be branched or
unbranched. The alkyl group can also be substituted or unsub

30

stituted. For example, the alkyl group can be substituted With

limited to, cyclopropenyl, cyclobutenyl, cyclopentenyl,
cyclopentadienyl, cyclohexenyl, cyclohexadienyl, norbome

one or more groups including, but not limited to, optionally

substituted alkyl, cycloalkyl, alkoxy, amino, ether, halide,
hydroxy, nitro, silyl, sulfo-oxo, or thiol, as described herein.

35

A “loWer alkyl” group is an alkyl group containing from one
to six (e.g., from one to four) carbon atoms.

Throughout the speci?cation “alkyl” is generally used to
refer to both unsubstituted alkyl groups and substituted alkyl
groups; hoWever, substituted alkyl groups are also speci?

40

cally referred to herein by identifying the speci?c
is substituted With one or more halide, e. g., ?uorine, chlorine,
45

to an alkyl group that is substituted With one or more alkoxy

groups, as described beloW. The term “alkylamino” speci?
cally refers to an alkyl group that is substituted With one or
more amino groups, as described beloW, and the like. When
“alkyl” is used in one instance and a speci?c term such as

nyl, and the like. The term “heterocycloalkenyl” is a type of
cycloalkenyl group as de?ned above, and is included Within
the meaning of the term “cycloalkenyl,” Where at least one of
the carbon atoms of the ring is replaced With a heteroatom
such as, but not limited to, nitrogen, oxygen, sulfur, or phos

phorus. The cycloalkenyl group and heterocycloalkenyl
group can be substituted or unsubstituted. The cycloalkenyl
group and heterocycloalkenyl group can be substituted With
one or more groups including, but not limited to, optionally

substituent(s) on the alkyl group. For example, the term
“halogenated alkyl” speci?cally refers to an alkyl group that

bromine, or iodine. The term “alkoxyalkyl” speci?cally refers

carbon-based ring composed of at least three carbon atoms
and containing at least one carbon-carbon double bound, i.e.,
C:C. Examples of cycloalkenyl groups include, but are not

50

“alkylalcohol” is used in another, it is not meant to imply that

substituted alkyl, cycloalkyl, alkoxy, alkenyl, cycloalkenyl,
alkynyl, cycloalkynyl, aryl, heteroaryl, aldehyde, amino, car
boxylic acid, ester, ether, halide, hydroxy, ketone, aZide,
nitro, silyl, sulfo-oxo, or thiol as described herein.
The term “alkynyl” as used herein is a hydrocarbon group
of 2 to 24 carbon atoms With a structural formula containing
at least one carbon-carbon triple bond. The alkynyl group can
be unsubstituted or substituted With one or more groups

the term “alkyl” does not also refer to speci?c terms such as

including, but not limited to, optionally substituted alkyl,

“alkylalcohol” and the like.
This practice is also used for other groups described herein.

cycloalkyl, alkoxy, alkenyl, cycloalkenyl, alkynyl, cycloalky
nyl, aryl, heteroaryl, aldehyde, amino, carboxylic acid, ester,

That is, While a term such as “cycloalkyl” refers to both

55

unsubstituted and substituted cycloalkyl moieties, the substi
tuted moieties can, in addition, be speci?cally identi?ed
herein; for example, a particular substituted cycloalkyl can be
referred to as, e.g., an “alkylcycloalkyl.” Similarly, a substi
tuted alkoxy can be speci?cally referred to as, e.g., a “halo

60

The term “cycloalkyl” as used herein is a non-aromatic

carbon-based ring composed of at least three carbon atoms.

Examples of cycloalkynyl groups include, but are not limited

to, cycloheptynyl, cyclooctynyl, cyclononynyl, and the like.

genated alkoxy,” a particular substituted alkenyl can be, e.g.,
an “alkenylalcohol,” and the like. Again, the practice of using
a general term, such as “cycloalkyl,” and a speci?c term, such
as “alkylcycloalkyl,” is not meant to imply that the general
term does not also include the speci?c term.

ether, halide, hydroxy, ketone, aZide, nitro, silyl, sulfo-oxo, or
thiol, as described herein.
The term “cycloalkynyl” as used herein is a non-aromatic
carbon-based ring composed of at least seven carbon atoms
and containing at least one carbon-carbon triple bound.

The term “heterocycloalkynyl” is a type of cycloalkenyl
group as de?ned above, and is included Within the meaning of
65

the term “cycloalkynyl,” Where at least one of the carbon
atoms of the ring is replaced With a heteroatom such as, but

not limited to, nitrogen, oxygen, sulfur, or phosphorus. The
cycloalkynyl group and heterocycloalkynyl group canbe sub
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stituted or unsubstituted. The cycloalkynyl group and hetero
Structurel

cycloalkynyl group can be substituted With one or more

groups including, but not limited to, optionally substituted

/

alkyl, cycloalkyl, alkoxy, alkenyl, cycloalkenyl, alkynyl,
cycloalkynyl, aryl, heteroaryl, aldehyde, amino, carboxylic

N

acid, ester, ether, halide, hydroxy, ketone, aZide, nitro, silyl,

R1

'

,

>=X

N\R11

sulfo-oxo, or thiol as described herein.
R2

The term “aryl” as used herein is a group that contains any

0
R

carbon-based aromatic group including, but not limited to,

benZene, naphthalene, phenyl, biphenyl, phenoxybenZene,

R3

R5

N

R6

and the like. The term “aryl” also includes “heteroaryl,”
R4

Which is de?ned as a group that contains an aromatic group

that has at least one heteroatom incorporated Within the ring
of the aromatic group. Examples of heteroatoms include, but
are not limited to, nitrogen, oxygen, sulfur, and phosphorus.
Likewise, the term “non-heteroaryl,” Which is also included
in the term “aryl,” de?nes a group that contains an aromatic
group that does not contain a heteroatom. The aryl group can
be substituted or unsubstituted. The aryl group can be substi
tuted With one or more groups including, but not limited to,

R7
R9

R8
StructureZ

0

Rl

N/Kx
R11

\
R3

groups that are bound together via a fused ring structure, as in

R
R5

N

R6

R4
30

R7,
R9
R8

bearing one or more substituents as set forth above.

The term “arylalkyl” refers to aryl-substituted alkyl groups
and “substituted arylalkyl” refers to arylalkyl groups further

"

R2
25

naphthalene, or are attached via one or more carbon-carbon

bonds, as in biphenyl.
The term “alkylaryl” refers to alkyl-substituted aryl groups
and “substituted alkylaryl” refers to alkylaryl groups further

/
N

20

optionally substituted alkyl, cycloalkyl, alkoxy, alkenyl,
cycloalkenyl, alkynyl, cycloalkynyl, aryl, heteroaryl, alde
hyde, amino, carboxylic acid, ester, ether, halide, hydroxy,
ketone, aZide, nitro, silyl, sulfo-oxo, or thiol as described
herein. The term “biaryl” is a speci?c type of aryl group and
is included in the de?nition of “aryl.” Biaryl refers to tWo aryl

R10

and isomers, i.e. enantiomers, diastereomers, and geometri
35

bearing one or more substituents as set forth above.

The term “arylalkenyl” refers to aryl-substituted alkenyl
groups and “substituted arylalkenyl” refers to arylalkenyl

cal isomers thereof.
In the above structures, Where the tWo dotted bonds in
Structure 1 & Structure 2 can be either single bonds or double
bonds, or a combination of both. When a double bond is

present in Structure 2, the tWo possible E and Z forms are

groups further bearing one or more substituents as set forth 40 included.

above.

In the above formulas, X is chosen from O or N. Where R

is hydrogen atom; methyl group; phenyl or substituted phenyl

The term “arylalkynyl” refers to aryl-substituted alkynyl
groups and “substituted arylalkynyl” refers to arylalkynyl
groups further bearing one or more substituents as set forth

above.
The term “aroyl” refers to aryl-substituted species such as

45

benZoyl and “substituted aroyl” refers to aroyl moieties fur
ther bearing one or more substituents as set forth above.

The term “heteroaryl” refers to cyclic moieties containing

50

one or more heteroatoms as part of the ring structure, and

having in the range of 3 up to 12 carbon atoms and “substi

tuted heteroaryl” refers to heterocyclic moieties further bear
ing one or more substituents as set forth above.

The term “acyl” refers to alkyl-carbonyl species.

55

A pharmaceutical composition containing a compound of
the invention is also contemplated, Which may include a
conventional additive, such as a stabiliZer, buffer, salt, preser
vative, ?ller, ?avor enhancer and the like, as knoWn to those

The term “halogen” refers to ?uoride, chloride, bromide or
iodide atoms.

As indicated above, an aspect of the present invention is the
treatment of cancers including, for example, lung carcino

group. R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 and R1 l are each
independently selected from hydrogen; alkyl; substituted
alkyl; cycloalkyl; substituted cycloalkyl, alkenyl; substituted
alkenyl; alkynyl; substituted alkynyl; aryl; substituted aryl;
alkylaryl; substituted alkylaryl; arylalkyl; substituted aryla
lkyl; arylalkenyl; substituted arylalkenyl; arylalkynyl; substi
tuted arylalkynyl; arylalkenyl; substituted arylalkenyl; aryla
lkynyl; substituted arylalkynyl; heteroaryl; substituted
heteroaryl; tri?uoromethyl; halogen; cyano; nitro; amidinea;
amino; carboxyl; ester; alkylalkylamino; dialkylamino;
hydroxyl; alkoxy or arylalkoxy (e.g. methoxy, ethoxy, ben
Zyloxy, substituted benZyloxy).

skilled in the art. Representative buffers include phosphates,
60

mas, breast cancers, prostate cancers, cancers of the cervix

carbonates, citrates and the like. Exemplary preservatives
include EDTA, EGTA, BHA, BHT and the like. A composi

and endometrium, neuroblastomas, lymphomas, gliomas,

tion of the invention may be administered orally, i.e., in solid

melanomas, squamous cell carcinomas, sarcomas, adenocar
cinomas, astrocytomas, head-and-neck tumors, and G1

or liquid form (tablet, gel cap, time release capsule, poWder,

tumors.

One embodiment of the present invention is compounds of

the folloWing formulae:

65

solution, or suspension in aqueous or non aqueous liquid;
intravenously as an infusion or injection, i.e., as a solution,

suspension or emulsion in a pharmaceutically acceptable car
ner.
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Examples of the present invention speci?c include the fol

ing cancer metastasis; or preventing the onset or development
of cancer (chemoprevention) in a mammal, for example a
human.
As discussed above, the methods of the present invention

lowing compounds:

are useful in the treatment in a Wide variety of cancers, includ

ing but not limited to solid tumors, hematological malignan
cies, carcinomas, neuroblastoma, or melanoma.
The invention further relates to pharmaceutical combina
tions useful for the treatment of cancer. The pharmaceutical
combination comprises a ?rst amount of a compound of the

present invention, e.g., compound 1, and a second amount of
an anti-cancer agent. The ?rst and second amount together
comprise a therapeutically effective amount.
The invention further relates to the use of a ?rst amount of

a compound of the present invention and a second amount of
an anti-cancer agent for the manufacture of a medicament for
treating cancer.
R
LRICN

RIIH
20

2.R:COOCH3 RIIH
lRIH

RIIH

4.R:NO2

RIIH

5.R:H

RlICl

6.R:H

RIIOCH3
O

In particular embodiments of this invention, the combina
tion of the compound of the present invention and anti-cancer
agent is additive, i.e. the combination treatment regimen pro
duces a result that is the additive effect of each constituent
When it is administered alone. In accordance With this
embodiment, the amount of a compound of the present inven
tion and the amount of the anti-cancer together constitute an

25 effective amount to treat cancer.

In another particular embodiment of this invention, the
combination of a compound of the present invention and

NH

/ N/KO

anti-cancer agent is considered therapeutically synergistic
When the combination treatment regimen produces a signi?
30

cantly better anticancer result (e.g., cell groWth arrest, apop
tosis, induction of differentiation, cell death) than the additive
effects of each constituent When it is administered alone at a
therapeutic dose. Standard statistical analysis can be
employed to determine When the results are signi?cantly

N

35

better. For example, a Mann-Whitney Test or some other

generally accepted statistical analysis can be employed.
The treatment procedures can take place sequentially in

R1

any order, simultaneously or a combination thereof. For
example, the ?rst treatment procedure, administration of a

R

7. RICN
s. RIH

RIIH
RIIH

RZIH
RZIH

9. RINOZ
lO.R:Cl
ll.R:COOCH3
12.R:H
13.R:F
14.R:H

RIIH
RIIH
RIIH
RIIBI
RIIH
RIIH

RZIH
RZIH
RZIH
RZIH
RZIH
RZICI

15.R:OCH3

RIIH RZIBI

16.R:H
17.R:H
18.R:H

RIIH
RIIH
RIIH

19.R:CH3

RIIH
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compound of the present invention, can take place prior to the
second treatment procedure, i.e. the anti-cancer agent, after
the second treatment With the anticancer agent, at the same
time as the second treatment With the anticancer agent, or a

45

RZICH3
RZIBI
RZIOCH3
RZIH
50

combination thereof. For example, a total treatment period
can be decided for a compound of the present invention
inhibitor. The anti-cancer agent can be administered prior to
onset of treatment With the compound of the present invention

or folloWing treatment With the compound of the present
invention. In addition, treatment With the anti-cancer agent
can be administered during the period of compound of the
present invention administration but does not need to occur

over the entire compound of the present invention treatment

Another embodiment of the present invention is the use of
compounds disclosed herein in connection With at least one
knoWn anti-cancer treatment.

period. Similarly, treatment With the compound of the present
invention can be administered during the period of anti-can
55

Thus, embodiments of the present invention relates to a

method of treating cancer in a subject in need thereof, by
administering to a subject in need thereof a ?rst amount of a

compound of the present invention or a pharmaceutically
acceptable salt or hydrate thereof, in a ?rst treatment proce

60

dure, and a second amount of an anti-cancer agent in a second

treatment procedure, Wherein the ?rst and second amounts

together comprise a therapeutically effective amount.

the progression of cancer including cancer metastasis; inhib
iting, delaying or preventing the recurrence of cancer includ

entire anti-cancer agent treatment period. In another embodi
ment, the treatment regimen includes pre-treatment With one
agent, either the compound of the present invention or the
anti-cancer agent, folloWed by the addition of the second
agent for the duration of the treatment period.
In one particular embodiment of the present invention, the
compound of the present invention can be administered in
combination With any one or more of an additional compound

As discussed herein, treatment of cancer, as used herein,

refers to partially or totally inhibiting, delaying or preventing

cer agent administration but does not need to occur over the

65

of the present invention, an alkylating agent, an antibiotic
agent, an antimetabolic agent, a hormonal agent, a plant
derived agent, an anti-angiogenic agent, a differentiation

inducing agent, a cell groWth arrest inducing agent, an apop
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tosis inducing agent, a cytotoxic agent, a biologic agent, a
gene therapy agent, or any combination thereof.
The invention also includes methods of preventing the

achieve the maximum effect for a given individual. It is fur
ther understood by one skilled in the art that the dosage
administered to a individual being treated may vary depend
ing on the individuals age, severity or stage of the disease and

occurrence or progression of a cancer or a precancerous con

dition in a mammal comprising administering to the mammal
an effective amount of a composition comprising a compound
of the present invention and a pharmaceutically acceptable
carrier.
The present invention also includes methods of treating or
preventing cancer in a mammalian subject, comprising
administering an effective amount to the mammalian subject

response to the course of treatment. One skilled in the art Will

knoW the clinical parameters to evaluate to determine proper

dosage for the individual being treated by the methods
described herein.

Additional pharmaceutical methods may be employed to
control the duration of action. Controlled release preparations
may be achieved through the use of polymer to complex or
absorb the proteins or their derivatives. The controlled deliv

a pharmaceutical preparation comprising a chemopreventive
or chemotherapeutic compound of the present invention.

ery may be exercised by selecting appropriate macromol

ecules (for example polyester, polyamino acids, polyvinyl,

Cancer, as used herein includes, but is not limited to, malig
nant tumors, adenocarcinomas, carcinomas, sarcomas,

pyrrolidone, ethylenevinylacetate, methylcellulose, car

malignant neoplasms, and leukemias. In particular epithelial

boxymethylcellulose, or protamine sulfate) and the concen

cell derived cancers are intended to be encompassed by this

tration of macromolecules as Well as the methods of incorpo

invention. Examples of epithelial cell derived cancers that
may be treated by the methods described herein include, but

ration in order to control release. Alternatively, instead of

are not limited to, breast cancer, colon cancer, ovarian cancer,
lung cancer or prostate cancer. Such cancers may be caused

20

by, chromosomal abnormalities, degenerative groWth and
developmental disorders, mitogenic agents, ultraviolet radi

meriZation.
When oral preparations are desired, the component may be

ating (UV), viral infections, oncogenes, mutations in genes,
in-appropriate expression of a gene and presentation on a cell,
or carcinogenic agent.
Administration of the compositions of the present inven
tion may be for either a prophylactic or therapeutic use. When

25

combined With typical carriers/excipients, such as lactose,
sucrose, starch, talc magnesium stearate, crystalline cellu

lose, methyl cellulose, carboxymethyl cellulose, glycerin,
sodium alginate or gum arabic among others. The only limi
tation With resect to the carrier is that it does not deleteriously
react With the active compound or is not deleterious to the

provided prophylactically, a compound of the present inven
tion is provided in advance of any symptoms due to the cancer

incorporating these agents into polymeric particles, it is pos
sible to entrap these materials in microcapsules prepared, for
example, by coacervation techniques or by interfacial poly

30

recipient thereof.

af?icting the individual. Additionally, a compound of the

The pharmaceutical preparations can be steriliZed and if

present invention may be administered during or after cancer

desired mixed With auxiliary agents, e.g., lubricants, preser
vatives, stabiliZers, Wetting agents, emulsi?ers, salts for in?u
encing osmotic pressure, buffers, colorings, ?avorings and/or

treatment to help prevent the reoccurrence of cancer. The

prophylactic administration of the composition is intended as
a chemopreventive therapy and serves to either prevent ini

40

aromatic substances and the like Which do not deleteriously
react With the active compounds.
As stated above, the administration of the compositions or
of each individual component of the present invention may be
for either a prophylactic or therapeutic purpose. The methods
and compositions used herein may be used alone in prophy

45

lactic or therapeutic uses or in conjunction With additional
therapies knoWn to those skilled in the art in the prevention or
treatment of cancer. Alternatively the methods and composi
tions described herein may be used as adjunct therapy.
It Will be appreciated that the actual preferred amounts of

35

tiation of malignant cells or arrest or reverse the progression

of transformed premalignant cells to malignant disease.

When provided therapeutically the composition is pro
vided at or after the onset of the disease. The therapeutic
administration of the composition of this invention serves to
attenuate or alleviate the cancer or facilitate regression of the

cancer a?llicting the individual. The term individual is

intended to include any animal, preferably a mammal, and
most preferably a human. Veterinary uses are intended to be

encompassed by this de?nition.

active compounds used in a given therapy Will vary according
to the speci?c compound being utiliZed, the particular com
positions formulated, the mode of application, the particular

In one embodiment of this invention, individuals at high
risk for a particular cancer, or at high risk of reoccurrence of
a cancer or Who have knoWn risk factors are prophylactically

treated With the methods and compositions described herein.
By Way of example, such individuals may include those With

site of administration, etc. Optimal administration rates for a

a familial history for either early or late onset of cancer, and

given protocol of administration can be readily ascertained by
those skilled in the art using conventional dosage determina

individuals Who are being or have been treated for a cancer or

tion tests.

50

The present invention also comprises methods of treating

cancer-related illness.

General ranges of suitable effective prophylactic dosages
that may be used are about 0.1 mg/kg of body Weight per day

cancer comprising administering an anti-cancer agent, anti
55

to about 500 mg/kg/day, a further range is about 0.5 mg/kg/
day to about 250 mg/kg/day, and as a further range, about 1

pound of the present invention.

mg/kg/day to about 100 mg/kg/day.
The daily dose of the compound may be administered in a
single dose or in portions at various hours of the day. Initially,
a higher dosage may be required and may be reduced over
time When the optimal initial response is obtained. By Way of
example, treatment may be continuous for days, Weeks, or
years, or may be at intervals With intervening rest periods. The
dosage may be modi?ed in accordance With other treatments
the individual may be receiving. One of skill in the art Will
appreciate that individualiZation of do sage may be required to

cancer chemotherapy and/ or anti-cancer radiation treatment;
and administering a treatment enhancing amount of a com

Yet another method of the present invention is a method for
60

treating a malignancy in a mammal, comprising administer
ing a pharmaceutical compound or composition of the present
invention With a therapy selected from the group consisting of
radioimmunoconjugate administration, other forms of

radiopharmaceutical therapy, chemotherapy, external beam
therapy, surgery, and other anti-malignancy treatment.
65

Finally, another method of the present invention is a
method of treating cancer comprising (a) administering to a
patient in need of such treatment, a pharmaceutically-effec
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tive amount of a composition of the present invention and (b)
administering a therapy selected from radiation therapy and

Example 1

chemotherapy.
EXAMPLES

The following examples are put forth so as to provide those
of ordinary skill in the art With a complete disclosure and

description of hoW the compounds, compositions, articles,

10

devices and/ or methods claimed herein are made and evalu

ated, and are intended to be purely exemplary of the invention
and are not intended to limit the scope of What the inventors
regard as their invention. Efforts have been made to ensure

CN

accuracy With respect to numbers (e.g., amounts, tempera
ture, etc.), but some errors and deviations should be

accounted for. Unless indicated otherWise, parts are parts by

4-((3 -((2,4,6-trioxotetrahydropyrimidin-5 (6H)

Weight, temperature is in o C. or is at ambient temperature,
and pressure is at or near atmospheric.

ylidene)methyl)- 1 H -indol-1 -yl)meth-yl)b enZonitrile

(1)

Table 1: Table 1 shoWs the ef?ciency of various compounds
synthesiZed in the present investigation as radiation sensitiZ

A mixture of barbituric acid (1.28 g; 0.01 mol) and 4-((3

ers. The values Were given as fraction of the cells survived

formyl-1H-indol-1-yl)methyl)benZonitrile (2.60 g; 0.01 mol)

When compared to DMSO control. Compounds 3, 4, and 15
Were tested at 10 uM concentration. All other drugs Were
tested at 25 uM concentration.

25

in methanol (50 ml) Were stirred at room temperature. After
10 min the reaction mixture became a solid suspension and

the color of reaction mixture changed to yelloW color solid
suspension. The suspension continued to stir at room tem

TABLE 1
Survival
Treatment

30

Fraction

DMSO

1.00

DMSO + 6 Gy

0.34

3

0.94

3 + 6 Gy

0.43

4

0.93

4 + 6 Gy

0-14

5

0.96

5 + 4 Gy

0.45

6

0.87

6 + 6 Gy

0.51

11

0.84

11 + 6 Gy

0.29

12

0.99

12 + 6 Gy

0.40

13

1.07

13 + 6 Gy

0.33

14

0.8

14 + 6 Gy

0.38

15

0.73

15 + 6 Gy

0.32

35

perature for 5 hrs. Solid product Was separated by ?ltration
and Washed several times With cold methanol (3x5 ml). The
isolated yelloW solid recrystallized from methanol gave (1) as
a yelloW crystalline product; m.p. >300o C.; 1H NMR

(DMSO-d6): 6 5.81 (s, 2H), 7.33-7.36 (m, 2H), 7.43-7.45 (d,
2H), 7.61-7.64 (m, 1H), 7.82-7.84 (d, 2H), 7.90-7.93 (m, 1H),
8.68 (s, 1H), 9.63 (s, 1H), 11.07 (bs, 1H), 11.15 (bs, 1H); 13C
NMR (DMSO-d6): 6 49.7,109.4,110.5,110.8,111.8,117.9,

118.4,123.0,123.8,128.0,129.6,132.6,136.1,141.7,141.8,
142.6,159.2,162.9,164.1.
40

Example 2

45

50

coocH3
55

16

0.94

16 + 6 Gy

0.38

17

0.91

17 + 6 Gy

0.33

18

0.99

18 + 6 Gy

0.47

19

0.96

19 + 6 Gy

0.35

Methyl-4-((3 -((2,4,6-trioxotetrahydropyrimidin-5
(6H)-ylidene)methyl)-1H-indol-1yl)methyl)benZoate
(2)
60

A mixture of barbituric acid (1.28 g; 0.01 mol) and methyl

4-((3-formyl-1H-indol-1-yl)methyl)benZoate (2.93 g; 0.01
65

mol) in methanol (50 ml) Were stirred at room temperature.
After 10 min the reaction mixture became a solid suspension
and the color of reaction mixture changed to yelloW color
solid suspension. The suspension continued to stir at room
temperature for 5 hrs. Solid product Was separated by ?ltra
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tion and Washed several times With cold methanol (3><5 ml).
The isolated yelloW solid recrystallized from methanol gave
(2) as a yelloW crystalline product; m.p. >300° C.; 1H NMR

?asks With those obtained from control ?asks. Bar graphs
Were created using the above data (FIG. 4).

(DMSO-d6): 6 3.82 (s, 3H), 5.79 (s, 2H), 7.33-7.36 (m, 2H),
7.40-7.42 (d, 2H), 7.61-7.63 (m, 1H), 7.91-7.93 (m, 1H),
7.94-7.95 (d, 2H), 8.68 (s, 1H), 9.62 (s, 1H), 11.06 (bs, 1H),
11.14 (bs, 1H); 13C NMR (DMSO-d6): 6 49.9, 52.1, 109.2,
110.7, 111.8,117.8, 122.9,123.7,127.4,129.0,129.5, 129.6,
136.2,141.4,141.7,142.6,150.1,162.8,164.1,165.5.

HSP70 Expression Experiment
HT-29 cells Were plated and Were alloWed to groW to 75%

con?uency. The cells Were treated either With DMSO or drugs
for 2 hrs. Cells Were Washed With phosphate buffered saline

(PBS, pH 7.2), fresh medium Was added, and incubated at 37°
10

Example 3

C. for 5 hrs. Then the cells Were Washed 3 times With cold

PBS. Then, 150 pl of protein lysis buffer (50 mM Tris HCl, pH
7.5, 150 mM NaCl, 1% NP-40, 10 mM EDTA, 0.1% SDS,
0.5% deoxycholic acid and 10 pl/ml of protein inhibitor cock
tail (Sigma, cat #E8230) Was added and the cells Were
scraped. The lysate Was transferred to a fresh Eppendorf tube

(1.5 ml) and sonicated for 5 seconds. The lysate Was centri
fuged at 13000 rpm at 4° C. for 20 min. The supernatant Was
transferred to fresh tubes and protein Was measured from each
20

sample using a Biorad colorimetric assay. 20-40 pg of protein
Was taken in a fresh tube and Was added equal volume of 5x
Lemmeli buffer and the samples Were heated at 95° C. for 5

min. The samples Were cooled and centrifuged brie?y. The
samples Were loaded on polyacrylamide gels (10-12%) and
resolved by gel electrophoresis. Then the proteins Were trans

CN

ferred onto a nitrocellulose membrane and the membrane Was

blocked With 5% loW fat milk in TBS-T buffer (contains 0.2%
Tween-20). HSP70 antibodies Were diluted 2000 fold in 5%
milk in TBS-T and added to the membrane and shaken for 3-4

(Z) -4-((3 -((2,5 -dioxoimidaZolidin-4-ylidene)me
thyl)-1H-indol-1 -yl)methyl)benZo nitrile (7)

30

A mixture of hydantoin (1.00 g; 0.01 mol), 4-((3-formyl
1H-indol-1-yl)methyl)benZonitrile (2.60 g; 0.01 mol) and
ammonium acetate (0.77 g; 0.01 mol) in acetic acid (2.70 g;
0.045 mol) Were re?uxed for 10 hrs. The reaction mixture Was

35

cooled and Water (20 ml) Was added. Filtered the product and
Washed With cold Water (2><5 ml). The crude product Was
recrystallized from a mixture of methanol and ethyl acetate
(1 :1 v/v) gave (3) as a yelloW crystalline product; m.p. >300°

C.; 1H NMR (DMSO-d6): 6 5.56 (s, 2H), 6.73 (s, 1H), 7.13
7.23 (m, 2H), 7.44-7.46 (d, 2H), 7.51-7.53 (d, 1H), 7.56 (m,
3H), 8.30 (s, 1H), 10.15 (bs, 1H), 11.07 (bs, 1H); 13C NMR
(DMSO-d6): 6 49.8,100.4,118.2, 110.4,111.8,118.2, 120.4,
122.5,124.2,126.8,128.4,129.9,130.2,134.8,142.6,142.6,

Gel Mobility Shift Assay
40

HT-29 cells Were incubated at 37° C. for 2 hrs. in the

presence of various concentrations of drugs. After the treat

45

tions Were performed by adding 10-20 pg of cell extract to 0.2
50

ng of 32P-labeled, double-stranded oligonucleotide contain
ing rat Hsp70 heat shock element (Liu et al., 1993) in binding
buffer [20 mM Tris (pH 7.5), 100 mM NaCl, 1 mM DTT, 10%
glycerol, 0.05% NP-40, 5 mM MgCl2, 0.05 pg of poly dl-dC]
and incubating at 20° C. for 15 min. Competition binding

55

reactions Were performed by addition of a 100-fold excess of

Human colon carcinoma cells (HT-29) Were groWn in
DMEM/F-12 medium containing 10% fetal bovine serum
(FBS). The cells Were inoculated into T25 ?asks (200-600
DMSO. Cells Were treated either With carrier (DMSO) or

unlabeled HSE to the binding reaction.

drugs at 10-150 pM concentration. The ?asks Were incubated
at 37° C. for 30 mins. After 30 mins incubation, the cells Were
radiated using Cs source. The ?asks Were then incubated at
37° C. for 90 mins. The medium Was removed and Washed
With PBS. Fresh medium Was added to the ?asks and incu

Tubule Formation Assay
60

bated at 37° C. for several days (2-3 Weeks) to form colonies.
The cells Were ?xed With methanol-acetic acid (3 :1 ratio) and
stained With 1% crystal violet dye in methanol for 30 min. The
excess dye Was Washed aWay With de-ioniZed Water, and the
colonies Were counted. The plating e?iciency Was determined

by comparing the number of colonies obtained from treated

ment, cells Were Washed With PBS and fresh medium Was
added. The ?asks Were incubated another 5 hrs at 37° C. Gel
mobility shift assay Was done as described in Kim et al.

(2006). Brie?y, the nuclear protein Was extracted With buffer
containing 10 mM HEPES, 422 mM NaCl, 0.1 mM EGTA,
5.3% glycerol, and protease inhibitor cocktail. Binding reac

Experimental Protocols

cells per ?ask). All compounds/ drugs Were dissolved in

TBS-T. HRP conjugated secondary antibodies Were diluted
2000 fold in l-5% milk in TBS-T and incubated the mem
brane for 45 min With shaking. The membrane Was Washed 3
times With TBS-T for 10 min. each time. 10 ml of ECL
reagent (Amersham) Was added to the membrane for 1 min.
The membrane Was exposed to autoradiography ?lm and

developed (FIG. 3)

154.8, 164.8.

Plating E?iciency (PE)

hrs. Membranes Were Washed 3 times With 1-5% milk in

Human umbilical vascular endothelial cells (HUVECs)
(50,000 cells/Well) Were plated on Matrigel. After 30 min, the
cells Were treated either With DMSO or 25 pM Compound 1.

65

Tubule formation Was assessed by observing plates under
microscope. FIG. 6 is represents 24 hr time point for DMSO
and Compound 1.

As indicated above, throughout this application, various
references are mentioned. All references, speci?cally those
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listed below, are incorporated herein by reference in their
entirety and should be considered to be part of this applica

therefore not to be limited to the details disclosed herein but
is to be accorded the full scope of the claims so as to embrace

tion.

any and all equivalent apparatus and methods.
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herein in what is believed to be the most practical and pre
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(a) R2 is H, R5 is H, and R7 is CN; or
(b) R2 is H, R5 is H, and R7 is CN; or
(c) R2 is H, R5 is H, and R7 is N02; or
(d) R2 is H, R5 is H, and R7 is C1; or
(e) R2 is H, R5 is H, and R7 is COOCH3; or
(f) R2 is H, R5 is Br, and R7 is CN; or
(g) R2 is H, R5 is H, and R7 is F; or
(h) R2 is Cl, R5 is H, and R7 is CN; or
(i) R2 is Br, R5 is H, and R7 is OCH3; or
(i) R2 is CH3, R5 is H, and R7 is H; or
(k) R2 is Br, R5 is H, and R7 is H; or
(1) R2 is OCH3, R5 is H, and R7 is H; or
(m) R2 is H, R5 is H, and R7 is CH3; and pharmaceutical
compositions thereof.
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7. A compound of the following formula:

3. A compound of claim 1, of the following formula:

0

R10

/
N

Rl

>=X
N

R2
\
R3

\
R1 1

0R
R5

N

R6

R4
CN.

R7; wherein

R9

R8

4. A compound of claim 1, of the following formula:

R8; wherein
X is O or N; R is H, methyl, phenyl or substituted phenyl;
Rl-Rll are each independently selected from H, alkyl, sub

25

30

COOCH3.

stituted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl,
substituted alkenyl, alkynyl, substituted alkynyl, aryl, substi
tuted aryl, alkylaryl, substituted alkylaryl, arylalkyl, substi
tuted arylalkyl, arylalkenyl, substituted arylalkenyl, arylalky
nyl, substituted arylalkynyl, arylalkenyl, substituted
arylalkenyl, arylalkynyl, substituted arylalkynyl, heteroaryl,
substituted heteroaryl, tri?uoromethyl, halogen, cyano, nitro,
amidinea, amino, carboxyl, ester, alkylalkylamino, dialky
lamino, hydroxyl, alkoxy or arylalkoxy; and pharmaceutical
compositions thereof.
8. A compound of the following formula:

5. A compound of claim 2, of the following formula:
35

0

R10

/
N

— PIN/k0

R1

40

/'

N

R2

\

xX

I

\
R3

R

R11
R5

N

R6

45

R4
CN.

R7; wherein

R9

6. A compound of claim 1, of the following formula:

R8

50

X is O or N; R is H, methyl, phenyl or substituted phenyl;

Rl-Rll are each independently selected from H, alkyl,
55

60

substituted alkyl, cycloalkyl, substituted cycloalkyl, alk
enyl, substituted alkenyl, alkynyl, substituted alkynyl,
aryl, substituted aryl, alkylaryl, substituted alkylaryl,
arylalkyl, substituted arylalkyl, arylalkenyl, substituted
arylalkenyl, arylalkynyl, substituted arylalkynyl, aryla
lkenyl, substituted arylalkenyl, arylalkynyl, substituted
arylalkynyl, heteroaryl, substituted heteroaryl, tri?uo
romethyl, halogen, cyano, nitro, amidinea, amino, car

boxyl, ester, alkylalkylamino, dialkylamino, hydroxyl,

N02.

alkoxy or arylalkoxy; and pharmaceutical compositions
65

thereof.

9. A pharmaceutical composition comprising a compound
of formula 11, and a pharmaceutically acceptable carrier.
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10. A pharmaceutical composition comprising a com
pound of formula 12, and a pharmaceutically acceptable car
rier.
11. A pharmaceutical composition comprising a com
pound of formula 17, and a pharmaceutically acceptable car
rier.
12. A pharmaceutical composition comprising a com
pound of formula 18, and a pharmaceutically acceptable car
rier.

13. A pharmaceutical composition comprising a com
pound of formula 11, and a pharmaceutically acceptable car
rier.
14. A pharmaceutical composition comprising a com
pound of formula 11, and a pharmaceutically acceptable car
rier.

